Prime Medicine PRME Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $77.8M+1.4% | $76.72M-9.8% | $85.09M+26.1% | $67.5M-36.3% | $105.94M-46.1% | ||
| $71.39M-37.7% | $114.65M— | —— | —— | —— | ||
| $0— | —— | -$120K-200% | $120K+606% | $17K— | ||
| $137.89M-23.9% | $181.29M-21.7% | $231.41M+90.8% | $121.29M-25.9% | $163.77M-22.7% | ||
| $18.82M-8.5% | $20.57M-6.7% | $22.05M-7.5% | $23.83M-4.5% | $24.96M+2.3% | ||
| $294.73M-14.0% | $342.73M-11.0% | $385.01M+38.0% | $279.01M-15.0% | $328.16M+10.3% | ||
| $12.33M+38.7% | $8.89M-5.0% | $9.35M+46.7% | $6.38M-36.4% | $10.03M-11.7% | ||
| $7.32M-6.4% | $7.82M+12.6% | $6.95M-16.4% | $8.32M+1.2% | $8.21M+15.8% | ||
| $36.29M-3.1% | $37.45M+6.9% | $35.02M+2.7% | $34.11M-0.5% | $34.29M-9.7% | ||
| $218.03M-1.7% | $221.87M-0.6% | $223.19M+2.3% | $218.15M-1.4% | $221.24M+53.3% | ||
| 775M0.0% | 775M0.0% | 775M0.0% | 775M0.0% | 775M+38,749,900% | ||
| -$937.48M-5.5% | -$888.35M-5.5% | -$842.28M-6.4% | -$791.69M-7.1% | -$739.1M-7.6% | ||
| $76.7M-36.5% | $120.87M-25.3% | $161.82M+166% | $60.86M-43.1% | $106.92M-30.2% | ||
| $294.73M-14.0% | $342.73M-11.0% | $385.01M+38.0% | $279.01M-15.0% | $328.16M+10.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Prime Medicine's total assets?
- Prime Medicine (PRME) holds $294.7M in total assets, down 10.2% year over year.
- How much debt does Prime Medicine have?
- Prime Medicine carries $114.5M in total debt against $76.7M of shareholders' equity, a debt-to-equity ratio of 1.49.
- How much cash does Prime Medicine have?
- Prime Medicine holds $77.8M in cash and equivalents.
- Can Prime Medicine cover its short-term obligations?
- Its current ratio is 3.80 — current assets exceed current liabilities.
- Where does Prime Medicine's balance sheet data come from?
- Every line is extracted from Prime Medicine's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
